AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18405155
Drug: Cetirizine Hydrochloride,
RxNorm normalized name: Cetirizine Hydrochloride, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine Hydrochloride, 10 mg orally, once daily for 10 days.
Trial: 12514658
Drug: Zofenopril (30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril (30-60 mg/day)
Trial: 12514658
Drug: Lisinopril (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (5-10 mg/day)
Trial: 10462245
Drug: MF59-adjuvanted influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted influenza vaccine (FLUAD)
Trial: 8698756
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (150 mg/day) for seven days before operation
Trial: 2016621
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) alone (CYC/ADR)
Trial: 2016621
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with concurrent radiation therapy (CT/RT)
Trial: 19042940
Drug: Trimethoprim (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (100 mg)
Trial: 6992677
Drug: Nitrofurantoin macrocrystals
RxNorm normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin macrocrystals (100 mg)
Trial: 6992677
Drug: Trimethoprim-sulfamethoxazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (40 mg/200 mg)
Trial: 31868819
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug and wedge-shaped pillow (WSP) treatment for 3 months after 2 weeks of drug only and drug plus WSP sequences.
Trial: 31868819
Drug: Drug only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug only sequence for 2 weeks.
Trial: 31868819
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug and WSP treatment after 3 months.
Trial: 28671507
Drug: Clarithromycin (CLM)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CLM) 500 mg every 12 hours for 3 days with one-stage full-mouth ultrasonic debridement (FMUD)
Trial: 17628232
Drug: Anti-integrin α4
RxNorm normalized name: Anti-alpha4 integrin
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-integrin α4 therapies
Trial: 17628232
Drug: Immunostimulating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunostimulating therapy (granulocyte-monocyte colony-stimulating factor)
Trial: 19627686
Drug: New therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New therapies
Trial: 15149889
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg/day (Control)
Trial: 9204086
Drug: Adapalene aqueous
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene aqueous 0.03% and 0.1% gels
Trial: 9204086
Drug: Adapalene alcoholic
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene alcoholic 0.03% and 0.1% gels
Trial: 9204086
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel vehicles or patch alone
Trial: 3630816
Drug: MLCu250 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLCu250 + 0.3 mg estradiol releasing about 1 microgram per day
Trial: 3630816
Drug: MLCu250 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLCu250 + 1.0 mg estradiol releasing about 3 micrograms per day
Trial: 29147969
Drug: Dietary phospholipids
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary phospholipids (PLs) at 8.5 g kg‐1
Trial: 29147969
Drug: Dietary phospholipids
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary phospholipids (PLs) at increasing levels (8.5 to 41.5 g kg‐1)
Trial: 27648684
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg Engerix-B® with 0, 1, 6 month intervals
Trial: 27648684
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg Kangtai hepatitis B vaccine with 0, 1, 6 month intervals
Trial: 27648684
Drug: 60 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 μg Kangtai hepatitis B vaccine with 0, 2 month intervals
Trial: 27648684
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg Huabei hepatitis B vaccine with 0, 1, 6 month intervals
Trial: 23153657
Drug: Switching therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching therapy for non-responders
Trial: 22323416
Drug: Oral antidiabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antidiabetes drugs (OADs)
Trial: 15739544
Drug: Enoxaparin treatment
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin treatment (40 mg subcutaneously once daily)
Trial: 6438014
Drug: Enteral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutritional support (constant infusion of a defined diet by needle catheter jejunostomy, started at 12 hours postoperatively, reaching 3000 kcal/day within 72 hours)
Trial: 6438014
Drug: Conventional nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional nutritional treatment (control group)
Trial: 31106550
Drug: Fentanyl (0.003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.003 mg/kg)
Trial: 28296480
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (HDG) - 3 classes per week for 12 weeks
Trial: 28296480
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (LDG) - 2 classes per week for 12 weeks
Trial: 28296480
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (HDG)
Trial: 28296480
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (LDG)
Trial: 25272965
Drug: computer-assisted cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: computer-assisted cognitive-behavioral therapy and/or medication management (ITV)
Trial: 24136890
Drug: Prognostic model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic model for overall survival (OS) in men treated with second-line chemotherapy
Trial: 16617400
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CA 15‐3, ICTP, and CEA
Trial: 10700536
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (Group I, n=15)
Trial: 10700536
Drug: Hypocaloric parenteral
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric parenteral nutrition (Group II, n=7)
Trial: 10700536
Drug: Hypocaloric parenteral
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric parenteral nutrition (Group II)
Trial: 1391107
Drug: Conventional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fluid therapy (Control Group I)
Trial: 1391107
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy based on glycerol and aminoacid (Group III)
Trial: 6437257
Drug: Leaflets (L)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaflets (L)
Trial: 6437257
Drug: Leaflets plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaflets plus maintenance manual (L + M)
Trial: 31567637
Drug: Split-dose polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose polyethylene glycol with electrolyte solution
Trial: 31567637
Drug: Full single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full single-dose polyethylene glycol with electrolyte solution
Trial: 22866767
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment (≥3 concomitantly used antihypertensive medications)
Trial: 22866767
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (≤2 concomitantly used antihypertensive medications)
Trial: 20560814
Drug: g‐FOBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: g‐FOBT
Trial: 17388709
Drug: Rapid initiation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid initiation of quetiapine (200 mg on day 1, 400 mg on day 2, 600 mg on day 3, 800 mg on day 4)
Trial: 17388709
Drug: Conventional initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional initiation of quetiapine (50 mg on day 1, 100 mg on day 2, increased in 100 mg/day increments to reach 400 mg on day 5)
Trial: 12392586
Drug: Endothelin-1 (ET-1)
RxNorm normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin-1 (ET-1) infusion at 2.5 pmol min-1
Trial: 12392586
Drug: Endothelin-1 (ET-1)
RxNorm normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin-1 (ET-1) infusion at 10 pmol min-1
Trial: 7750527
Drug: Low-dose BCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose BCG (75 mg)
Trial: 7750527
Drug: Standard-dose BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose BCG (150 mg)
Trial: 2125243
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of pravastatin daily for 24 weeks
Trial: 2125243
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of pravastatin daily for 24 weeks
Trial: 2125243
Drug: 24 gm
RxNorm normalized name: Lactated Ringer's Solution/Magnesium Sulfate 24 GM/500 ML Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 gm of cholestyramine daily for 24 weeks
Trial: 2125243
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of pravastatin plus 24 gm of cholestyramine daily for 24 weeks
Trial: 374162
Drug: Phyllocontin Continus
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllocontin Continus tablets
Trial: 437308
Drug: Alupent tablets
RxNorm normalized name: metaproterenol sulfate Oral Tablet [Alupent]
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alupent tablets
Trial: 437308
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllocontin tablets alone
Trial: 437308
Drug: Ventolin tablets
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin tablets alone
Trial: 437308
Drug: Phyllocontin tablets
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllocontin tablets with inhaled Ventolin
Trial: 437308
Drug: Ventolin tablets
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin tablets with inhaled Ventolin
Trial: 30393978
Drug: Fructose breath
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose breath tests (open twice and blinded once)
Trial: 26233594
Drug: 3 IA
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 IA doses of PRP
Trial: 26233594
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of PRP
Trial: 26233594
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of HA
Trial: 26233594
Drug: 3 IA
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 IA doses of PRP (early OA subgroup)
Trial: 26233594
Drug: Any treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment group (advanced OA subgroup)
Trial: 25920297
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone (8 mg) and metoclopramide (10 mg)
Trial: 25920297
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg) with normal saline solution (1.6 ml)
Trial: 24013497
Drug: Low-dose GH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GH therapy (0.025 mg/kg/day)
Trial: 24013497
Drug: High-dose GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GH therapy (0.05 mg/kg/day)
Trial: 24013497
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (0.05 mg/kg/day for 12 months)
Trial: 19826305
Drug: Standard stretching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard stretching protocol (daily for 4 weeks, then discontinued)
Trial: 11996943
Drug: Atorvastatin (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10-40 mg)
Trial: 6680215
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment
Trial: 10505027
Drug: Radiation or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation or chemotherapy alone
Trial: 2371573
Drug: Diane contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane contraceptive pill
Trial: 2371573
Drug: Microgynon 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgynon 50 contraceptive pill
Trial: 30240471
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe)
Trial: 27022625
Drug: Naloxone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone administration in healthy individuals
Trial: 27022625
Drug: Naloxone administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone administration in chronic pain patients
Trial: 21505219
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and Vitamin D (1g calcium and 400 IU vitamin D daily)
Trial: 10688158
Drug: Olanzapine 15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 15 mg
Trial: 13680082
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg doxepin (single i.v.)
Trial: 13680082
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg doxepin (subchronic p.o.)
Trial: 10584984
Drug: Prednisone 10
RxNorm normalized name: prednisone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 10 mg/day starting 1 month before ovulation induction for patients positive for ovarian autoantibodies (ov-ab).
Trial: 10584984
Drug: Seronegative study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seronegative study group (no treatment).
Trial: 17611232
Drug: Oral co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-amoxiclav
Trial: 7787537
Drug: Intravenous followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous followed by oral co-amoxiclav
Trial: 7787537
Drug: Intravenous followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous followed by oral cephalosporins
Trial: 2081065
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy plus diazepam
Trial: 2081065
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy alone
Trial: 2081065
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy plus placebo
Trial: 2081065
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy (either alone or in combination)
Trial: 30063297
Drug: Albiglutide 50
RxNorm normalized name: ALBIGLUTIDE 50MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 50 mg liquid formulation from an auto-injector (Regimen A)
Trial: 30063297
Drug: Lyophilized albiglutide
RxNorm normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lyophilized albiglutide 50 mg from a DCC pen-injector (Regimen B)
Trial: 22369287
Drug: vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin 50 mg qd
Trial: 22369287
Drug: vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin 50 mg bid
Trial: 17660482
Drug: vildagliptin 100
RxNorm normalized name: vildagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin 100 mg qd
Trial: 12678168
Drug: Zuclopenthixol acetate
RxNorm normalized name: zuclopenthixol acetate
DrugBank: Zuclopenthixol (DB01624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuclopenthixol acetate (ZPTA) 50-100 mg
Trial: 12678168
Drug: Haloperidol (HAL)
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol (HAL) 5-10 mg
Trial: 7622272
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg at bedtime for 12 months
Trial: 7622272
Drug: Macrocrystalline nitrofurantoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrocrystalline nitrofurantoin 50 mg at bedtime for 12 months
Trial: 29233615
Drug: Higher HEI‐2010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher HEI‐2010 score in women with prior chemotherapy
Trial: 24131168
Drug: Heroin administration
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin administration
Trial: 23104147
Drug: Single-injection sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection sciatic nerve block combined with continuous femoral nerve block (group Fs)
Trial: 16890834
Drug: fosamprenavir-ritonavir 700
RxNorm normalized name: fosamprenavir 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosamprenavir-ritonavir 700 mg/100 mg twice daily
Trial: 16890834
Drug: lopinavir-ritonavir 400
RxNorm normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir-ritonavir 400 mg/100 mg twice daily
Trial: 15253741
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron administration (40 mg of saccharated ferric oxide after every dialysis session for four weeks)
Trial: 15253741
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vehicle treatment)
Trial: 11509476
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (2-hour)
Trial: 16682305
Drug: Implantable cardioverter‐defibrillator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter‐defibrillator (ICD) therapy
Trial: 3443058
Drug: Plain felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plain felodipine tablets, 10mg bid for 10 days
Trial: 24955731
Drug: DHA diet
RxNorm normalized name: CHOLECALCIFEROL 0.25 mg in 1 g / CHONDRUS CRISPUS 350 mg in 1 g / ASCORBIC ACID 90 mg in 1 g TOPICAL CAPSULE [NIWEDAH BLACK SEED ASHWAGANDHA DIETARY SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA diet supplementation (1.14 g per day for eight weeks)
Trial: 18201893
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (15 ml bolus, 10 ml every 6h)
Trial: 18201893
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (20 ml bolus, 15 ml every 6h)